| Azafaros–BioGeneration Ventures: investment, 202002 financing round Series A totalling €25m incl existing + co-investor BiGV |
2020-02-06 |
| Azafaros–BioMedPartners: investment, 202002 financing round Series A totalling €25m incl co-investor BioMedPartners |
2020-02-06 |
| Azafaros–Forbion: investment, 202002 financing round Series A totalling €25m incl lead investor Forbion |
2020-02-06 |
| Azafaros–SEVERAL: investment, 202002 financing round Series A €25m led by Forbion with participation from BioMedPartners + BGV |
2020-02-06 |
| Azafaros–Trophic Communications: public relations, 202002 service existent by Trophic Communications |
2020-02-06 |
| Catalent–SEVERAL: investment, 202002 underwritten public offering $500m+$75m with approx $330m intented to finance MaSTherCell acquisition |
2020-02-03 |
| Orgenesis–Catalent: investment, 202002 acquisition $315m in cash of MaSTherCell Global Inc from Great Point Partners + SFPI-FPIM + Orgenesis Inc |
2020-02-03 |
| iTeos Therapeutics–Wallonia (govt): grant?, 202001 non-dilutive funding €11.5m for ph1b/2a of EOS-850 from Walloon Region |
2020-01-30 |
| iTeos Therapeutics–Wallonia (govt): grant?, 202001 non-dilutive funding €3.5m for ph1 of EOS-448 from Walloon Region |
2020-01-30 |
| iOnctura–SEVERAL: investment, 202001 financing round Series A €15m led by Inkef Capital + co-led by VI Partners |
2020-01-23 |
| PDC*line Pharma–SEVERAL: investment, 202001 financing round Series B €13.9m with existing + new investors |
2020-01-22 |
| Fibrocor Therapeutics–Galapagos: investment, 202001 equity investment by Galapagos as part of expanded collaboration |
2020-01-15 |
| Galapagos–Fibrocor Therapeutics: fibrosis drug, 202001– collab developm expansion excl license option for 4 addit small molecule inhibitor programmes |
2020-01-15 |
| NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group |
2020-01-10 |
| NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C USD22m led by existing investors BIVF + PPF Group wih all private investors |
2020-01-10 |
| NorthSea Therapeutics–BioGeneration Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor BGV |
2020-01-08 |
| NorthSea Therapeutics–Forbion: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Forbion |
2020-01-08 |
| NorthSea Therapeutics–New Science Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor NSV |
2020-01-08 |
| NorthSea Therapeutics–Novo Group: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Novo Seeds |
2020-01-08 |
| NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio |
2020-01-08 |
| NorthSea Therapeutics–Sofinnova: investment, 202001 financing round Series B totalling €36m incl new + co-investor Sofinnova Investments |
2020-01-08 |
| NorthSea Therapeutics–VenBio: investment, 202001 financing round Series B totalling €36m incl new + lead investor VenBio Partners |
2020-01-08 |
| Wellington Partners–MC Services: public relations, 202001 service existent by MC Services |
2020-01-08 |
| Augustine Therapeutics–SEVERAL: investment, 201912 seed financing round €4.2m from V-Bio Ventures + PMV + Advent France + Gemma Vrisius + VIB |
2019-12-16 |
| Promethera–SEVERAL: investment, 201912 financing round Series D extension €7.5m bringing total round to €47.2m |
2019-12-16 |
| ImCheck Therapeutics–Boehringer: investment, 201912 financing round Series B totalling €48m incl existing + co-investor BIVF |
2019-12-04 |
| ImCheck Therapeutics–Gimv: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Gimv |
2019-12-04 |
| ImCheck Therapeutics–Idinvest Partners: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Idinvest Partners |
2019-12-04 |
| ImCheck Therapeutics–Kurma: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Kurma Partners |
2019-12-04 |
| ImCheck Therapeutics–Life Sciences Partners: investment, 201912 financing round Series B totalling €48m incl existing + co-investor LSP |
2019-12-04 |
| ImCheck Therapeutics–SEVERAL: investment, 201912 financing round Series B €48m co-led by Bpifrance + Pfizer Ventures |
2019-12-04 |
| ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB |
2019-11-29 |
| LabCorp–Qiagen: bioinformatics, 201911– license extension with HGMD in addition ot Qiagen Clinical Insights |
2019-11-20 |
| Kuros–SEVERAL: investment, 201911–201912 capital increase CHF12.5m with 6.405m new registered shares at CHF1.95/share |
2019-11-19 |
| Zelluna–Glycostem Therapeutics: cell therapy contract manufacturing, 201911– collab developm + supply of TCR-guided NK-cell therapies |
2019-11-19 |
| Acticor Biotech–SEVERAL: investment, 201911 financing round Series B extension €7m led by new investorGO Capital bringing Series B to €22.3m |
2019-11-06 |
| Argenx–SEVERAL: investment, 201911 global offering $557m with 4.6m ordinary shares incl in the form of ADSs |
2019-11-06 |
| AVCare–Acticor Biotech: investment, 201911 acquisition 100% of AVCare by Acticor Biotech |
2019-11-06 |
| Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market |
2019-10-28 |
| SMS-Oncology–Cato Research: investment, 201910 merger €na |
2019-10-28 |
| OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m |
2019-10-23 |
| Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
| Amarna Therapeutics–Flerie Invest: investment, 201910 financing round totalling €10m incl lead investor Flerie Invest AB + incl RVO innovation credit |
2019-10-16 |
| Amarna Therapeutics–Netherlands (govt): credit, 201910 financing round totalling €10m incl substantial innovation credit from RVO.nl |
2019-10-16 |
| Amarna Therapeutics–PERSON: investment, 201910 financing round totalling €10m incl existing + co-investor Pim Berger + incl RVO innovation credit |
2019-10-16 |
| Amarna Therapeutics–SEVERAL: investment, 201910 financing round €10m led by Flerie Invest AB + incl innovation credit from RVO.nl |
2019-10-16 |
| Ra Pharmaceuticals–UCB: investment, 201910– acquisition $2.5b in cash for $48/share incl acquired net cash of $315m ANNOUNCED |
2019-10-10 |
| N-Side–Sciad Communications: public relations, 201910 service existent by Sciad |
2019-10-09 |
| Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w |
2019-10-07 |
| Immunexpress–SEVERAL: investment, 201910 private financing round |
2019-10-03 |
| Univercells–EU (govt): credit, 201910– EIB loan €20m to advance vaccine portfolio |
2019-10-03 |
| AstraZeneca–N-Side: clinical supply chain management s/w, 201910– supply implementation of cloud-based N-Side Suite for Clincial Trials |
2019-10-01 |
| Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) |
2019-10-01 |
| Oncimmune–IPF Partners: credit, 201909– 202309 credit facility €8.5m four year incl warrant for 2m new ordinary shares IPF Management SA |
2019-09-20 |
| Menarini–BlueBee: bioinformatics, –201909 collab developm of MSBiosuite using BlueBee genomics data platoform |
2019-09-19 |
| Novigenix–BioLizard: bioinformatics, 201909– collab developm of AI-based bioinformatics algorithm to support developm of tests for LITOseek platform |
2019-09-19 |
| Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB |
2019-09-18 |
| Celyad–LifeSci: public relations, 201909 service existent PR+ IR for US by LifeSci PR + LifeSci Advisors |
2019-09-16 |
| Celyad–Ulysse Communication: public relations, 201909 service existent for Europe by Ulysse |
2019-09-16 |
| OTHER–Curetis: molecular diagnostics, 201909– collab r+d + option for NGS-based antibiotic resistance testing of Ares Genetics with global IVD firm |
2019-09-16 |
| Pharvaris–Bain Capital: investment, 201909 financing round Series B totalling $66m incl new + co-investor Bain Capital Life Sciences |
2019-09-10 |
| Pharvaris–Foresite Capital: investment, 201909 financing round Series B totalling $66m incl new + lead investor Foresite Capital |
2019-09-10 |
| Pharvaris–Idinvest Partners: investment, 201909 financing round Series B totalling $66m incl existing + co-investor Idinvest Partners |
2019-09-10 |
| Pharvaris–Kurma: investment, 201909 financing round Series B totalling $66m incl existing + co-investor Kurma Partners |
2019-09-10 |
| Pharvaris–Life Sciences Partners: investment, 201909 financing round Series B totalling $66m incl existing + co-investor LSP |
2019-09-10 |
| Pharvaris–Rockefeller: investment, 201909 financing round Series B totalling $66m incl new + co-investor Venrock Partners |
2019-09-10 |
| Pharvaris–SEVERAL: investment, 201909 financing round Series B $66m led by Foresite Capital |
2019-09-10 |
| Pharvaris–VenBio: investment, 201909 financing round Series B totalling $66m incl new + co-investor venBio Partners |
2019-09-10 |
| iStar Medical–Belgium (govt): investment, 201909 financing round Series C totalling €40m incl existing + co-investor SFPI-FPIM |
2019-09-05 |
| iStar Medical–BNP Paribas: investment, 201909 financing round Series C totalling €40m incl new + co-investor BNP Paribas Fortis Private Equity |
2019-09-05 |
| iStar Medical–Capricorn Venture Partners: investment, 201909 financing round Series C totalling €40m incl existing + co-investor Capricorn |
2019-09-05 |
| iStar Medical–Earlybird: investment, 201909 financing round Series C totalling €40m incl new + co-investor Earlybird |
2019-09-05 |
| iStar Medical–Gimv: investment, 201909 financing round Series C totalling €40m incl new + co-lead investor Gimv |
2019-09-05 |
| iStar Medical–Life Sciences Partners: investment, 201909 financing round Series C totalling €40m incl new + co-lead investor LSP Health Economics 2 |
2019-09-05 |
| iStar Medical–Optimum Strategic Communications: public relations, 201909 service existent by Optimum |
2019-09-05 |
| iStar Medical–SEVERAL: investment, 201905 financing round Series C €40m led by LSP + Gimv |
2019-09-05 |
| iStar Medical–Wallonia (govt): investment, 201909 financing round Series C totalling €40m incl existing + co-investor SRIW |
2019-09-05 |
| Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity |
2019-09-04 |
| Uniqure–SEVERAL: investment, 201909 public offering $225m+$34m with 4.9m+734k ordinary shares at $46/share |
2019-09-04 |
| Achilles Therapeutics–RA Capital Management: investment, 201909 financing round Series B totalling £100m incl new + lead investor RA Capital |
2019-09-03 |
| Achilles Therapeutics–SEVERAL: investment, 201909 financing round Series B £100m led by RA Capital Management |
2019-09-03 |
| Curetis–HC Wainwright: investment banking, 201908– supply service Curetis retains HC Wainwright to evaluate all strategic options |
2019-08-12 |
| Blue Heron–Eurofins: investment, 201908 acquisition of Blue Heron Biotech by Eurofins Genomics LLC |
2019-08-06 |
| Imcyse–Andrew Lloyd Associates: public relations, 201908 service existent by ALA |
2019-08-05 |
| Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP |
2019-07-31 |
| Ako med–Curetis: Unyvero system, 201907– distribution excl 3y Unyvero A50 system + cartridges in Serbia + Bosnia + North Macedonia + Montenegro |
2019-07-30 |
| Breath Therapeutics–Zambon: investment, 201907 acquisition €140m + €360m milestones by Zambon |
2019-07-25 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| AM-Pharma–SEVERAL: investment, 201907 financing round €116m co-led by LSP + Andera Partners |
2019-07-16 |
| Ncardia–Evotec: investment, 201907 acquisition €na of iPSC assets + 17 strong team of bankrupt Ncardia AG in Cologne |
2019-07-15 |
| Galapagos–Gilead: investment, 201907 equity investment $1.1b at €140.59/share raising share from 12.3% to 22% as part of collab |
2019-07-14 |
| Gilead–Galapagos: drug research + development, 201907–202906 strategic 10y collab $3.9b upfront + $1.1b equity investment + milestones |
2019-07-14 |
| Citryll–BrightGene: investment, 201907 first closing of a targeted €15m financing round Series A incl investor BrightGene International Ltd |
2019-07-03 |
| Citryll–Curie Capital: investment, 201907 first closing of a targeted €15m financing round Series A incl investor Curie Capital |
2019-07-03 |
| Citryll–ModiQuest: investment, 201907 first closing of a targeted €15m financing round Series A incl investor ModiQuest BV |
2019-07-03 |
| Citryll–Netherlands (govt): investment, 201907 first closing of a targeted €15m financing round Series A incl investor BOM Brabant Ventures |
2019-07-03 |
| Citryll–SEVERAL: investment, 201907 first closing of targeted €15m financing round Series A with ModiQuest + BOM + BrightGene + Curie Capital |
2019-07-03 |
| CryoTherapeutics–SEVERAL: investment, 201906 financing round Series B €7m incl equity + debt + non-dilutive cash advances |
2019-06-27 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
